title: Novel opportunities for thymidylate metabolism as a therapeutic target.
abstract: For over 40 years, the fluoropyrimidine 5-fluorouracil (5-FU) has remained the central agent in therapeutic regimens employed in the treatment of colorectal cancer and is frequently combined with the DNA-damaging agents oxaliplatin and irinotecan, increasing response rates and improving overall survival. However, many patients will derive little or no benefit from treatment, highlighting the need to identify novel therapeutic targets to improve the efficacy of current 5-FU-based chemotherapeutic strategies. dUTP nucleotidohydrolase (dUTPase) catalyzes the hydrolysis of dUTP to dUMP and PPi, providing substrate for thymidylate synthase (TS) and DNA synthesis and repair. Although dUTP is a normal intermediate in DNA synthesis, its accumulation and misincorporation into DNA as uracil is lethal. Importantly, uracil misincorporation represents an important mechanism of cytotoxicity induced by the TS-targeted class of chemotherapeutic agents including 5-FU. A growing body of evidence suggests that dUTPase is an important mediator of response to TS-targeted agents. In this article, we present further evidence showing that elevated expression of dUTPase can protect breast cancer cells from the expansion of the intracellular uracil pool, translating to reduced growth inhibition following treatment with 5-FU. We therefore report the implementation of in silico drug development techniques to identify and develop small-molecule inhibitors of dUTPase. As 5-FU and the oral 5-FU prodrug capecitabine remain central agents in the treatment of a variety of malignancies, the clinical utility of a small-molecule inhibitor to dUTPase represents a viable strategy to improve the clinical efficacy of these mainstay chemotherapeutic agents.
authors.affiliation: Department of Pathology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Room 5322, 1441 Eastlake Avenue, Los Angeles, CA 90089, USA.
authors.forename: Peter M
authors.initials: PM
authors.lastname: Wilson
authors.forename: William
authors.initials: W
authors.lastname: Fazzone
authors.forename: Melissa J
authors.initials: MJ
authors.lastname: LaBonte
authors.forename: Jinxia
authors.initials: J
authors.lastname: Deng
authors.forename: Nouri
authors.initials: N
authors.lastname: Neamati
authors.forename: Robert D
authors.initials: RD
authors.lastname: Ladner
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology / Q000473:pathology; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000201:enzymology / Q000473:pathology; D045744:Cell Line, Tumor; D019295:Computational Biology; D004249:DNA Damage; D015195:Drug Design; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D007150:Immunohistochemistry; D011755:Pyrophosphatases / Q000037:antagonists & inhibitors*; D015203:Reproducibility of Results; D013936:Thymidine / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D011755:Pyrophosphatases; C020020:dUTP pyrophosphatase; D005472:Fluorouracil; D013936:Thymidine
references.citation: Mol Pharmacol. 1980 Nov;18(3):513-20
references.pmid: 6110169
references.citation: J Clin Oncol. 2004 Feb 1;22(3):529-36
references.pmid: 14752076
references.citation: Int J Cancer. 1999 Dec 22;84(6):614-7
references.pmid: 10567908
references.citation: Clin Colorectal Cancer. 2006 Nov;6(4):261-4
references.pmid: 17241510
references.citation: Curr Top Med Chem. 2002 Mar;2(3):211-27
references.pmid: 11944817
references.citation: J Clin Oncol. 1999 Mar;17(3):1061-70
references.pmid: 10071301
references.citation: Clin Cancer Res. 2000 Apr;6(4):1322-7
references.pmid: 10778957
references.citation: Structure. 1996 Sep 15;4(9):1077-92
references.pmid: 8805593
references.citation: Biochem Pharmacol. 1997 Sep 1;54(5):635-8
references.pmid: 9337081
references.citation: J Clin Oncol. 2001 Nov 1;19(21):4097-106
references.pmid: 11689577
references.citation: Nature. 1957 Mar 30;179(4561):663-6
references.pmid: 13418758
references.citation: Cancer Res. 2002 Sep 1;62(17):4909-15
references.pmid: 12208740
references.citation: Pharmacogenetics. 2004 May;14(5):319-27
references.pmid: 15115918
references.citation: Pharmacogenomics J. 2001;1(1):65-70
references.pmid: 11913730
references.citation: Cancer Res. 2000 Jul 1;60(13):3493-503
references.pmid: 10910061
references.citation: Lancet. 2000 Mar 25;355(9209):1041-7
references.pmid: 10744089
references.citation: N Engl J Med. 2004 Jun 3;350(23):2335-42
references.pmid: 15175435
references.citation: Cancer Res. 2003 Jun 1;63(11):2898-904
references.pmid: 12782596
references.citation: J Mol Biol. 1997 Apr 4;267(3):727-48
references.pmid: 9126849
references.citation: Nucleic Acids Symp Ser. 1995;(34):77-8
references.pmid: 8841560
references.citation: Cancer Res. 1991 May 1;51(9):2346-52
references.pmid: 2015598
references.citation: Clin Cancer Res. 1998 May;4(5):1243-50
references.pmid: 9607583
references.citation: J Clin Oncol. 2004 Jan 15;22(2):229-37
references.pmid: 14657227
references.citation: Br J Cancer. 2000 Sep;83(6):792-9
references.pmid: 10952785
references.citation: Eur J Cancer. 1998 Jul;34(8):1274-81
references.pmid: 9849491
references.citation: Cancer Res. 1995 Apr 1;55(7):1407-12
references.pmid: 7882343
references.citation: J Clin Oncol. 2002 Apr 1;20(7):1721-8
references.pmid: 11919227
references.citation: Cancer Res. 2007 Feb 1;67(3):940-5
references.pmid: 17283124
references.citation: J Bacteriol. 1988 Mar;170(3):1069-75
references.pmid: 2830228
references.citation: Nat Rev Cancer. 2003 May;3(5):330-8
references.pmid: 12724731
references.citation: N Engl J Med. 2006 Dec 28;355(26):2733-43
references.pmid: 17192538
references.citation: Mol Pharmacol. 2004 Sep;66(3):620-6
references.pmid: 15322254
references.citation: Anal Biochem. 1989 Aug 1;180(2):222-6
references.pmid: 2554751
references.citation: J Clin Oncol. 2000 Jan;18(1):136-47
references.pmid: 10623704
references.citation: Cancer Res. 1994 May 1;54(9):2296-8
references.pmid: 8162567
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5210-7
references.pmid: 17968020
references.citation: Mol Pharmacol. 1982 Jan;21(1):211-6
references.pmid: 6215571
references.citation: Clin Pharmacokinet. 1989 Apr;16(4):215-37
references.pmid: 2656050